Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Positions Curium as leading manufacturer of Lu-177 isotope
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Nadda noted that TB treatment coverage in India has increased from 59% to 85%
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance
Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies
Announces Rs. 317 crore investment in new recycling plant
Overall investment in the US facility is estimated around US$50 million
Subscribe To Our Newsletter & Stay Updated
